1. Medtech Insight

CMS To Pay Co-Surgeons For Transcatheter Valve Procedures, But At Lower Value Than Sought By Physicians

Surgeons and cardiologists who perform transcatheter aortic valve replacement procedures will be paid for the total amount of their work in 2013, but CMS’ adoption of a lower relative value unit for TAVR will result in a lower payment amount.

Clinicians who perform transcatheter aortic valve replacements reacted favorably to CMS’ decision to continue its co-surgery payment policy for the procedure in the 2013 final physician fee schedule, but the agency’s use of lower-than-recommended work relative value units for TAVR was less than welcome.

In its final rule, issued Nov. 1, CMS opted to set RVUs to “reflect the total physician work of the procedures, and to continue to follow our co-surgery...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

More from Medtech Insight

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 
• By Natasha Barrow

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.

FDLI: Clinical Labs Face Uncertainty After Texas Court’s LDT Ruling

 
• By Elizabeth Orr

A Texas court's decision against US FDA regulation of lab-developed tests (LDTs) has introduced new uncertainties for clinical labs. Industry stakeholders are now worried about potential future regulations while also managing existing compliance requirements. Recent conference discussions underscored the complexities of FDA oversight.